Feature|Articles|August 29, 2026

Top 5 Spinal Muscular Atrophy Headlines of 2026: What Neurologists Should Know

In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy from 2026, 5 headlines compiled in one place by the NeurologyLive® team.

Spinal muscular atrophy (SMA), a rare neuromuscular disorder, saw regulatory and clinical trial activity across several treatment approaches in 2026, including antisense oligonucleotides (ASOs), gene replacement therapy, and an investigational muscle-directed add-on agent. Below are 5 notable SMA developments from this year so far from the NeurologyLive^® team, in honor of SMA Awareness Month this August.

Related to this article

October 14th, 2026

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression

A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

October 16th, 2026

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

October 17th, 2026

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

October 16th, 2026

NeurologyLive® Friday 5 — October 16, 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

October 16th, 2026

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

October 16th, 2026

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

October 16th, 2026

Episode 177: Previewing the 2026 NEALS Annual Meeting

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

October 15th, 2026

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.